Informations:
Erreur:
ID
34575
Description
Diindolylmethane in Treating Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01391689
Lien
https://clinicaltrials.gov/show/NCT01391689
Mots-clés
Versions (1)
- 19/01/2019 19/01/2019 -
Détendeur de droits
see on clinicaltrials.gov
Téléchargé le
19 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Stage IA Breast Cancer NCT01391689
Eligibility Stage IA Breast Cancer NCT01391689
- StudyEvent: Eligibility
Similar models
Eligibility Stage IA Breast Cancer NCT01391689
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
ID.1
Item
prescribed tam as adjuvant therapy for early stage (0, i, ii, iiia) breast cancer or as chemoprevention in women at high risk for breast cancer
boolean
ID.2
Item
new or planned prescription of tam therapy; ineligible for randomization until on tam for > 3 months with the expectation to continue use for > 18 months
boolean
ID.3
Item
mammogram with breast imaging reporting and data system (birads) score of >= 2; (equivalent to the following and similar breast density descriptive terms found in mammogram reports: 2 = scattered fibroglandular elements/densities; 3 = heterogeneously dense tissue; 4 = extremely dense tissue)
boolean
ID.4
Item
no use of soy-based dietary supplements or willingness to discontinue use, complete a 4-week wash-out period, prior to randomization, and refrain from use during trial period
boolean
ID.5
Item
if pre-menopausal, non-pregnant (confirmed with urinary pregnancy test); practicing birth control or s/p oophorectomy
boolean
ID.6
Item
able to complete study run-in activities, including taking study-provided placebo pill twice daily (am & pm) and recording pill intake and any symptoms experienced on a study calendar, with a compliance rate of at least 80%
boolean
ID.7
Item
normal blood chemistry test that includes sodium and specific kidney and liver function tests (creatinine, alanine amino transferase-alt, aspartate amino transferase-ast) within 30 days of study enrollment; (informed consent form signed)
boolean
ID.8
Item
no history of hyponatremia
boolean